Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation

The molecule “T cell immunoreceptor with immunoglobulin and ITIM domain,” or TIGIT, has recently received much attention as a promising target in the treatment of various malignancies. In spite of the quick progression of anti-TIGIT antibodies into clinical testing both as monotherapy and in combina...

ver descrição completa

Detalhes bibliográficos
Principais autores: Jin-Hwan Han, Mingmei Cai, Jeffery Grein, Samanthi Perera, Hongmei Wang, Mike Bigler, Roenna Ueda, Thomas W. Rosahl, Elaine Pinheiro, Drake LaFace, Wolfgang Seghezzi, Sybil M. Genther Williams
Formato: Artigo
Idioma:English
Publicado em: Frontiers Media S.A. 2020-10-01
coleção:Frontiers in Immunology
Assuntos:
TIGIT
FcγR
myeloid cells
combination cancer immunotherapy
costimulatory molecules
immune checkpoint blockade
Acesso em linha:https://www.frontiersin.org/article/10.3389/fimmu.2020.573405/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.573405/full

Registros relacionados